Get started
Author

Wenjing Zhang

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
2010 · S. Kasichayanula, X. Liu, et al. · Diabetes Obesity and Metabolism · 89
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
2015 · Y. Sunakawa, S. Stintzing, et al. · Annals of Oncology · 55
Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma
2009 · G. Lurje, H. Husain, et al. · Annals of Oncology · 51
PDF
Effect of a high‐fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects
2011 · S. Kasichayanula, X. Liu, et al. · Diabetes Obesity and Metabolism · 49
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
2011 · A. B. El-Khoueiry, R. K. Ramanathan, et al. · Investigational New Drugs · 47
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials
2017 · M.D. Berger, S. Stintzing, et al. · Annals of Oncology · 38
Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer
2014 · Y. Sunakawa, S. Stremitzer, et al. · Annals of Oncology · 30
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy
2021 · J.Y. Wang, J. Xiu, et al. · Annals of Oncology · 27
PDF
The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy
2013 · G Absenger, L Benhaim, et al. · The Pharmacogenomics Journal · 20
Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases
2015 · S. Stremitzer, W. Zhang, et al. · Annals of Oncology · 14
PDF
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer
2011 · M.J. LaBonte, P.M. Wilson, et al. · Annals of Oncology · 14
PDF
Genetic variants associated with colorectal brain metastases susceptibility and survival
2015 · S Stremitzer, A S Berghoff, et al. · The Pharmacogenomics Journal · 11
Association of a germ-line variant in the K-ras 3’ untranslated region with response and progression-free survival in patients with mCRC treated with single-agent cetuximab (IMCL-0144) or in combination with cetuximab (EPIC) independent of K-ras mutation status
2009 · T. Winder, W. Zhang, et al. · Journal of Clinical Oncology · 6
Polymorphisms in angiogenesis related genes predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)
2007 · O. S. Shaye, H. M. Chang, et al. · Journal of Clinical Oncology · 5
Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy.
2011 · A. Gerger, W. Zhang, et al. · Journal of Clinical Oncology · 3
Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3
2018 · M.D. Berger, S. Stintzing, et al. · Annals of Oncology · 1
Molecular differences between colorectal cancers with mutations in histone modifiers genes vs wild-type (WT) tumors
2018 · A. Puccini, K. Poorman, et al. · Annals of Oncology · 1
PDF
Use of insulin-like growth factor (IGF) pathway polymorphism IGF1R_rs2016347 to predict tumor recurrence in estrogen receptor–positive breast cancer patients.
2011 · T. Winder, G. Giamas, et al. · Journal of Clinical Oncology · 1
Association of germline polymorphisms in genes involved in the CD44 pathway and clinical outcome in localized gastric adenocarcinoma (GA).
2010 · Y. Ning, T. Winder, et al. · Journal of Clinical Oncology · 1
Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line irinotecan (IR)+/− cetuximab (CB): The EPIC experience
2009 · D. Yang, A. Pohl, et al. · Journal of Clinical Oncology · 1
Association of CD133 polymorphisms and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with either first-line 5-FU + bevacizumab (BV) or second-line irinotecan (IR)/cetuximab (CB) or IR alone
2009 · A. Pohl, W. Zhang, et al. · Journal of Clinical Oncology · 1
Long non-coding RNAs in colorectal cancer: shaping the tumour microenvironment and advancing precision oncology
2026 · M. Bartolini, F. Battaglin, et al. · Nature Reviews Gastroenterology & Hepatology
Neurotransmitter-associated structural remodeling of the insula-hippocampus mediates cognitive impairment in age-related hearing loss
2026 · Yao Wang, Wenqing Li, et al. · Neurobiology of Disease
CCL2/CCR2-mediated monocyte-macrophages infiltration drives methamphetamine-induced depressive-like behaviors
2025 · Chunling Ma, Congcong Hou, et al. · Research Square
PDF
P1.03-02 Combinationof Anlotinib and Tislelizumab for Lung Adenocarcinoma: Effects on Metabolic and Flora Microenvironment
2023 · Y. Nie, Z. Yang, et al. · Journal of Thoracic Oncology
PDF
Works count: 33
Citation count: 465
H-index: 11
I10-index: 12
Year
Topic
Type